| 心房颤动患者卒中防治药物利伐沙班与华法林的药物经济学分析 |
| |
| 引用本文： | 李伟,孟昭慧,刘兆华.心房颤动患者卒中防治药物利伐沙班与华法林的药物经济学分析[J].中国药物经济学,2021(2). |
| |
| 作者姓名： | 李伟 孟昭慧 刘兆华 |
| |
| 作者单位： | 山东大学齐鲁医学院药学院;济南市莱芜人民医院 |
| |
| 摘 要： | 目的对心房颤动患者卒中防治药物利伐沙班与华法林进行药物经济学评价。方法本研究对心房颤动卒中的患者制订了两种治疗方案,华法林片(A组)、利伐沙班片(B组),运用药物经济学知识(成本-效果分析及敏感性分析)对利伐沙班和华法林预防心房颤动相关卒中进行药物经济学评价。结果利伐沙班组与华法林组比较增量成本-效果比(ICER)是508565元/QALYs元,即每多获得1个QALYs需要多花508565元。结论我国大部分地区华法林用于预防心房颤动卒中与利伐沙班比较具备成本优势。
|
| 关 键 词： | 抗凝药物 心房颤动 药物经济学 |
Pharmacoeconomic Analysis of Rivaroxaban and Warfarin For Stroke Prevention and Treatment in Patients with Atrial Fibrillation |
| |
| LI Wei,MENG Zhao-Hui,LIU Zhao-Hua.Pharmacoeconomic Analysis of Rivaroxaban and Warfarin For Stroke Prevention and Treatment in Patients with Atrial Fibrillation[J].China Journal of Pharmaceutical Economics,2021(2). |
| |
| Authors: | LI Wei MENG Zhao-Hui LIU Zhao-Hua |
| |
| Institution: | (School of Pharmacy,Qilu Medical College,Shandong University,Jinan 250012,China;Laiwu People's Hospital,Jinan 271100,China) |
| |
| Abstract: | Objective To analyze the pharmacoeconomics of rivaroxaban and warfarin,which are used to prevent stroke in patients with atrial fibrillation.Methods In this study,2 treatment plans have been formulated for patients with atrial fibrillation stroke,warfarin tablets(group A)and rivaroxaban tablets(group B).The knowledge of pharmacoeconomics(cost-effect analysis and sensitivity analysis)was applied for rivaroxaban and warfarin for the prevention of strokes related to atrial fibrillation for pharmacoeconomic evaluation.Results The ICER of rivaroxaban group and Warfarin group was 508565 yuan/QALYs yuan,that is,each additional QALYs would cost 508565 yuan.Conclusion Warfarin has a cost advantage over Rivaroxaban in the prevention and treatment of patients with stroke in atrial fibrillation in most parts of China. |
| |
| Keywords: | Anticoagulants Atrial fibrillation Pharmacoeconomics |
| 本文献已被 维普 等数据库收录！ |
|
